Clinical Trials Demonstrate Monitoring PD-L1 Upregulation Using LifeTracDx Blood Test Could Support New Treatment Path for Metastatic Triple Negative Breast Cancer

MONMOUTH JUNCTION, N.J., May 30, 2025 /PRNewswire/ — Creatv Bio, a Division of Creatv MicroTech, Inc. (“Creatv”) in collaboration with CytoDyn Inc. (“CytoDyn”) presents promising four-year survival rates from a pooled clinical trial analysis of patients with metastatic triple-negative…